Skip to content
Screener

Integra LifeSciences IART Q3 2026 earnings

Reported October 21, 2026 · Before market open

Revenue$411.2MMiss by $2.0M
EPS$0.59Beat by $0.03
Revenue estimate$413.2M
EPS estimate$0.56
“Our third quarter performance reflected mixed results across our portfolio, with stronger performance in Specialty Surgery partially offset by a $7 million impact from the Cincinnati disruption and softer-than-expected results in Tissue Reconstruction. We delivered results within our guidance ranges, generated strong cash flow, reduced leverage, and subsequently completed our debt refinancing. Our updated outlook reflects both the recovery timeline in Cincinnati and more measured expectations for portions of our Tissue Reconstruction business. We are focused on executing against these challenges while continuing to support our customers, advance key product launches and returns, and strengthen the business for more consistent long-term growth.”
Stuart Essig

Next report

Date not yet announced

Financials

Q3 2026

Income statement

See full
Revenue$411.2M+2.3%
Gross profit$209.9M+1.4%
Operating income$18.9M+60.7%
Net income$14.9M+375%
EPS (diluted)$0.19+371%

Balance sheet

See full
Cash & equivalents$252.3M+8.6%
Total debt$1.9B-2.6%
Total equity$1.1B+2.8%
Total assets$3.5B-3.8%

Cash flow

See full
Operating cash flow$96.0M+135%
CapEx$10.2M-32.4%
Free cash flow$85.7M—

Valuation & ratios

Valuation

as of 10/30/26
See full
Market cap$997.82M+8.4%
Enterprise value$2.62B+0.3%
P/E76.7×—
P/S0.6×0.0×

Profitability

See full
Gross margin52.4%0.0pp
Operating margin3%+1.6pp
Net margin0.8%—
FCF margin5.2%—

Returns & leverage

See full
Return on equity1.2%—
Debt / equity1.8×-0.1×
Current ratio3.6×+0.5×

Segments

By product

See full
Neurosurgery$214.1M+6.2%
Wound Reconstruction Solutions$81.5M—
Surgical Instruments$49.7M—
ENT Solutions$40.4M—
Corporate Partnerships$25.5M—

By geography

See full
Asia Pacific$47.9M+12.3%
Europe$42.3M-1.4%
Rest of World$21.6M+4.9%

By segment

See full
Specialty Surgery$304.1M—
Tissue Reconstruction$107.1M—

FAQ

When did Integra LifeSciences report Q3 2026 earnings?
Integra LifeSciences (IART) reported Q3 2026 earnings on October 21, 2026 before market open.
What were Integra LifeSciences's Q3 2026 revenue and EPS?
Integra LifeSciences reported revenue of $411.2M and eps of $0.59 for Q3 2026.
Did Integra LifeSciences beat estimates in Q3 2026?
Revenue missed the consensus estimate of $413.2M by $2.0M. EPS beat the consensus estimate of $0.56 by $0.03.
How did Integra LifeSciences's Q3 2026 results compare year-over-year?
Compared to the same quarter a year prior, revenue grew 2.3% from $402.1M a year earlier and eps grew 9.3% from $0.54.
Where can I find Integra LifeSciences's Q3 2026 SEC filings?
You can read the 8-K earnings release (0001193125-26-425271) and the 10-Q periodic report (0000917520-26-000077) directly on SEC EDGAR. The filing index links above go to sec.gov.